arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

RESMED INC

RMD
$212.06 ▼ -11.35 (-5.08%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
69 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

RESMED INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $30.8B
Dividend Yield 0.28%
Revenue Growth 10.8%
Op. Margin 34.9%
ROIC 5.8%
FCF / Share $3.58
Trailing P/E 77.4x
Price / Book 4.7x
FCF Yield 1.7%
Debt / Equity 0.10
info Valuation on last close. End-of-day price, Aug 7, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.43B
↑ +10.8%
Net Income Profit after all expenses
$348.54M
↑ +11.9%
Operating Margin Operating profit as % of sales
34.9%
↑ +1.0% 89th
FCF / Share Free cash flow per share
$3.58
↑ +67.8%
Long-Term Debt Long-term obligations
$404.17M
— +0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
90
Returns
89
Financial Health
87
Cash Quality
72

Dividend History

Dividend / share · sourced from SEC filings
$2.12 Latest / share
+10.4% YoY
+7.1% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 69 quarters